Mitsubishi Tanabe Pharma Canada Announces That Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Quebec
TORONTO, April 29, 2020 /CNW/ -Mitsubishi Tanabe Pharma Corporation Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), today announced that RADICAVA® (edaravone) is now listed on the Régie de l'assurance maladie du Québec (RAMQ) formulary (special authorization). RADICAVA is an intravenous infusion treatment for amyotrophic lateral sclerosis (ALS), a rapidly progressive, neurodegenerative and fatal disease.1
"The listing of RADICAVA on the Quebec public formulary is an important step in our long-term commitment to the ALS community in Canada," said Atsushi Fujimoto, President, MTP-CA. "We thank the Government of Quebec for its leadership in making this treatment available to patients in Quebec who are eligible for coverage under the Quebec Public Prescription Drug Insurance Plan."
MTP-CA continues to have discussions with other provinces, territories and federal agencies regarding the listing of RADICAVA under publicly funded drug programs.
About RADICAVA® (edaravone)
About Mitsubishi Tanabe Pharma Canada, Inc.
About Mitsubishi Tanabe Pharma America, Inc.
SOURCE Mitsubishi Tanabe Pharma Canada, Inc.